Go to
JCI Insight
Abstract
Lymphoid malignancies typically promote an infiltrate of immune cells at sites involved by the disease. While some of the immune cells present in lymphoma have effector function, the immune system is unable to eradicate the malignant clone. Therapies that optimize immune function therefore have the potential to improve the outcome of lymphoma patients. In this Review, we discuss immunologic approaches that directly target the malignant cell as well as approaches to optimize both the innate and adaptive immune response to the tumor. While many of these therapies have shown single-agent activity, the future will clearly require thoughtful combinations of these approaches.
Authors
Stephen M. Ansell, Yi Lin
Figure 1
Overview of immunotherapy in lymphoma.
Options:
View larger image
(or click on image)
Download as PowerPoint
ADC, antibody-drug conjugate; Ag, antigen; DC, dendritic cell; IMiDs, immunomodulatory drugs; MDSC, myeloid-derived suppressor cell; Teff, effector T cell; TKI, tyrosine kinase inhibitors; Treg, regulatory T cell. This figure was adapted from an image created by Arushi Khurana using BioRender.
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)